Skip to main content

Mouse ADAM9 Ectodomain Biotinylated Antibody

R&D Systems, part of Bio-Techne | Catalog # BAF949

R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
Loading...
BAF949

Key Product Details

Species Reactivity

Mouse

Applications

Flow Cytometry, Western Blot

Label

Biotin

Antibody Source

Polyclonal Goat IgG

Product Specifications

Immunogen

Mouse myeloma cell line NS0-derived recombinant mouse ADAM9
Glu215-Cys673
Accession # Q61072

Specificity

Detects mouse ADAM9 Ectodomain in Western blots. In Western blots, less than 1% cross-reactivity with recombinant human (rh) ADAM15, recombinant mouse (rm) ADAM15, rmADAM10, and rhTACE is observed.

Clonality

Polyclonal

Host

Goat

Isotype

IgG

Applications for Mouse ADAM9 Ectodomain Biotinylated Antibody

Application
Recommended Usage

Flow Cytometry

0.25 µg/106 cells
Sample: MCF-7 human breast cancer cell line

Western Blot

0.1 µg/mL
Sample: Recombinant Mouse ADAM9 (Catalog # 949-AD)

Formulation, Preparation, and Storage

Purification

Antigen Affinity-purified

Reconstitution

Reconstitute at 0.2 mg/mL in sterile PBS.

Reconstitution Buffer Available:
Size / Price
Qty
Loading...

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with BSA as a carrier protein.

Shipping

The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: ADAM9

ADAM9, also known as MDC9 or meltrin gamma, is a member of the ADAM family that contains a disintegrin and metalloprotease-like domain (1). Like other membrane‑anchored ADAMs, ADAM9 consists of a pro domain with a cysteine switch and furin cleavage sequence, a catalytic domain with the zinc-binding site and Met-turn expected for reprolysins, a disintegrin-like domain, a cysteine-rich domain, an EGF-like domain, a transmembrane domain, and the cytoplasmic domain. ADAM9 is able to cleave peptides corresponding to cleavage sites of tumor necrosis factor-alpha (TNF-alpha), the p75-TNF receptor, the beta-amyloid protein precursor, and the c-kit ligand-1, implying that it may participate in shedding of these membrane proteins (2). In fact, ADAM9 has been shown to shed membrane‑anchored heparin‑binding EGF-like growth factor (3). In addition, it also cleaves oxidized insulin B-chain and fibronectin (2, 4). Besides its catalytic activity, ADAM9 functions as an adhesion molelcule through binding of its disintegrin domain to integrins such as alphav beta5 and alpha6 beta1 (5, 6). The cytoplasmic domain of ADAM9 interacts with Src homology 3 (SH3)‑containing proteins and protein kinase C, and may mediate different signaling pathways (3, 7). ADAM9 is widely expressed in tissues (8).

References

  1. Moss, M.L. et al. (2001) Drug Discov. Today 6:417.
  2. Roghani, M. et al. (1999) J. Biol. Chem. 274:3531.
  3. Izumi, Y. et al. (1998) EMBO J. 17:7260.
  4. Schwettmann, L. and H. Tschesche (2001) Protein. Expr. Purif. 21:65. 
  5. Nath, D. et al. (2000) J. Cell Sci. 113:2319.
  6. Zhou, M. et al. (2001) Biochem. Biophys. Res. Comm. 280:574.
  7. Howard, L. et al. (1999) J. Biol. Chem. 274:31693.
  8. Weskamp, G. et al. (1996) J. Cell Biol. 132:717.

Long Name

A Disintegrin and Metalloprotease-like Domain 9

Alternate Names

MCMP, MDC9, Meltrin gamma

Entrez Gene IDs

8754 (Human); 11502 (Mouse)

Gene Symbol

ADAM9

UniProt

Additional ADAM9 Products

Product Documents for Mouse ADAM9 Ectodomain Biotinylated Antibody

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Product Specific Notices for Mouse ADAM9 Ectodomain Biotinylated Antibody

For research use only

Loading...
Loading...
Loading...
Loading...
Loading...